Effect of Strontium Ranelate on Vertebral Pain Syndrome and quality of life in Postmenopausal Women: Results of a Multicenter Ukrainian Study

The aim of the research was to study the effect of strontium ranelate on vertebral pain syndrome and quality of life in postmenopausal women with osteopenia and osteoporosis. 894 postmenopausal women were examined (average age 60.0 +/- 10.6 years, average weight - 71.3 +/- 13.4 kg, average height - 161.8 +/- 7.1 cm). The dynamics of vertebral pain syndrome and daily activities of the patients were assessed with a grade scale. In the group of patients who took strontium ranelate during 12 months the vertebral pain syndrome decreased by 58%, the daily activity increased by 92%; in the group of patients who received strontium ranelate during 8 months - the vertebral pain syndrome decreased by 48%, the daily activity increased by 82,97%; in the group of patients who received strontium ranelate during 4 months - the vertebral pain syndrome decreased by 29.17%, the daily activity increased by 41.84%. The patients suffered the following adverse events: dyspeptic effects (6.8%), allergic reactions (0.4%), headache (2%) and hypertension (0.4%). Thus, it has been demonstrated that the strontium ranelate treatment significantly decreases a pronounced vertebral pain syndrome, improves functional abilities and quality of life in postmenopausal women with osteopenia and osteoporosis. The treatment is conducted with a minimum number of side effects and is well tolerated by patients.